Can I read 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study on EtoBox?

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study by Perrin E. Romine; Lanell M. Peterson; Brenda F. Kurland; Darrin W. Byrd; Alena Novakova-Jiresova; Mark Muzi; Jennifer M. Specht; Robert K. Doot; Jeanne M. Link; Kenneth A. Krohn; Paul E. Kinahan; David A. Mankoff; Hannah M. Linden is a Medicine article available to read on EtoBox.

What is 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study about?

## Abstract ## Purpose This study evaluated the ability of^18^F-Fluorodeoxyglucose (FDG) and^18^F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors. ## Methods In two separate studies, women with early stage ER+ breast cancer underwent either paired FDG-PET (n = 22) or FLT-PET (n = 27) scans prior to endocrine therapy and again in the pre-operative setting. Tissue samples for Ki-67 were taken for all patients both prior to treatment and at the time of surgery. ## Results FDG maximum standardized uptake value (SUVmax) declined in 19 of 22 lesions (mean 17% (range −45 to 28%)). FLT SUVmax declined in 24 of 27 lesions (mean 26% (range −77 to 7%)). The Ki-67 index declined in both studies, from pre-therapy (mean 23% (range 1 to 73%)) to surgery [mean 8% (range < 1 to 41%)]. Pre- and post-therapy PET measures showed strong rank-order agreement with Ki-67 percentages for both tracers; however, the percent change in FDG or FLT SUVmax did not demonstrate a strong correlation with Ki-67 index change or Ki-67 at time of surgery

Who reads 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study?

Author

Perrin E. Romine; Lanell M. Peterson; Brenda F. Kurland; Darrin W. Byrd; Alena Novakova-Jiresova; Mark Muzi; Jennifer M. Specht; Robert K. Doot; Jeanne M. Link; Kenneth A. Krohn; Paul E. Kinahan; David A. Mankoff; Hannah M. Linden

Publisher

Springer Science and Business Media LLC

Published

2021

Language

EN

Field

Medicine (Health Sciences)